, , , ( ), , , ( ), . , , .
, .
. , , , . . . , , - .
80%. , , .
, .. , . ( , ) , . , (, ).
.
:
- () ( , .
().
( IIΙ, 2006) : (B1) (. 2).
2.
B1. 1 |
: 1. : a. () b. c. d. 2. ( ), 1 3- 6 |
B1a. 2 - |
: 1. , , , 2. (), , , 2 3- 6 1. 2. |
B1b. 3 |
: 1. , , 2. 3. 4. 5. 3 3- 6 1. , 2. , , , 3. - |
|
|
, , , , : , , , - , . , , , (, ), , .
:
1. .pylori
2. .
3. .
:
1. ( , ).
2. .
3. ( )
(alarm symptoms) (red flags). .
3
-
- , ,
( )
-
-
-
45
|
|
-
-
-
(overlap-) . , , , , . II , , , , . , ( ) , , , , . . . ( ), , . . ( ).
.
. pylori (test and treat) . . Test and treat , . . (peptic ulcer disease) , . . test and treat . pylori - . , ( ) . pylori (60-90 %), , , . test and treat . , , . , , . , . .
, , , . 7- , , (Sleisenger & Fordtran s Gastrointestinal and Liver Disease, 1998), , , .
(McQuaid, 1998)
- , . , . , .
-, - . , , .
|
|
- . , .
- , , , - .
- . , .
- .
C . . . , . . . , ( ) , . , , .
. . pylori. , . , , . - . 2- . 2- : 20 2 , 20 2 . ( 30 , 20 1 , 20 ).
, .
- , 8 % 12 . , , . ( 20 25%) c C .. ( ). -3 (2005 ) 14 ( ), ( 0,5 2 ), ( 1,0 2 ) ( 500 2 ), .. 40% , , , ; ─ ( , , , - 120 4 , 0,5 4 0,25 4 ).
|
|
, - . . ( ) , . . (20 30%) .
, , (), , (), , (), , , , .
, , , .
(1990), (1994). , .
I. : 1) Helicobacter pylori ( ); 2) ( ), 3) - ( ); 4) ( ); 4) (, , , .).
II. : , , / .
III. , , , H.p. .
().
. , , , . .. , , -. . , . .. .. , . . .. -.. IgG , .. , , MALT- (mucosa-associated lymphoid tissue ly mphmas); b- , .
() - , , , 12 . , , . , , I, . 12 () .
|
|
, , 3-18 , . .
- , . , - () , , . , (), , , .
. .. 80% . ..- , 85% , .. 80 90% , 40 70% , 25 30% . 1% . 16% . , , .
. . . , ( 12 ). , , G-, (). - - .
() . , , . , . . . , , , . .
. . . , ( 50% ), , .
(, ). , . 25 100 ( 4 7 100 ). , , . . 80% . , .., , .
. . , 4 . , .
, , , , , , , 25 , , () . 30 60 , . , . . ( , 10% ). , . , . , , , , , , / . ,
. (, , ) ( , ), ( ), (II-III ).
. H. pylori, . , , H.pylori , , , 2 , . , , 453, , .. .
. : (, , ); , (, ). (1% ), , (). , .
. 5 : 2 .
- , ( .., , ).
. , (, , .. , ), , , , - .
. 1. , , .. ( ) 12- .
2. ( 100 /).
3. : .. , ..
4. -: 6,0 . 2,0 .
5. .. (, , , , , .. ).
:
, .
Helicobacter pylori (3+), .
, , , . (. ). ( ) - , , - () , ( ), .
12 ─ ─ .
:
1. ?
.
.
.
.
2. , :
.
.
.
. -
. , ,
3. - ?
.
.
.
.
.
4. .p.(+)?
.
.
.
.
.
5. :
.
.
.
.
.
6. :
.
.
.
.
.
7. :
. ,
.
. /
.
.
8. :
.
. -
. 1-
. 2-
.
1. , , .
2. , , , , .
3. .
4. .
5. .
6. .
7. , .
8. .
., 25 , , , , 3 . . , , , . , , , , 100/70 ..., 68 . , , , , .
1. ,
2. .
3. .
.
1. : , -.
2. :
A. .
B. .
C. H.p. ( )
D. ( -)
3. .
A. , .
B. .
C. 10 3 .
1. .., .., .. . .: -, 1998; 483.
2. .. . nsilium medicum: , 2002; 3: 6 10.
3. .., .. - , H.pylori ( -3). nsilium medicum: , 2006; 1: 3 8.
4. .. . nsilium medicum: , 2006; 1: 8 12.
5. Carlsson R., Dent J., oiling-Sternevald E. et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol. 1998; 33:10231029.
6. Drossman D.A. The functional gastrointestinal disorders and the Rome ΙΙΙ process. Gastroenterolology. 2006; 130(5): 145965.
7. McQuaid K. Dispepsia. In: M. Feldman et al. (Eds.) Sleisenger and Fordtans gastrointestinal and liver disease, (6-th ed.) Philadelphia-London-Toronto-Montreal-Sydney-Tokyo, 1998; 105117.
8. Moayyedi P., Soo S., Decks J. et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane upper gastrointestinal and pancreatic diseases group. Cochrane Database Syst. Rev. 2003; (3):CD001960.
9. Peura DA., Kovacs TO., Metz DC. et al. Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am. J. Med. 2004; 116: 7408.
10. Tack J., Caenepeel P., Arts. J. et al. Lee KJ, Sifrim D, Janssens J. Prevalence and symptomatic impact of non-erosive reflux disease in functional dyspepsia. Gut. 2005; 54:13706.
11. Talley N.J., Meineche-Schmidt V., Pare P. et al. Efficiency of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and opera Studies). Aliment. Pharmacol. Ther. 1998; 12: 105565.
.. . .
, 2009 . 23 . .
: . , ., ... ..
664009, . 109.
500 .
, 2009 .